Cargando…

Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers

PURPOSE: Evaluate the pharmacodynamics, pharmacokinetics, and safety of paltusotine, an orally bioavailable, nonpeptide, somatostatin receptor subtype 2 (SST2) agonist being developed for the treatment of acromegaly and neuroendocrine tumors. METHODS: A randomized, double-blind, placebo-controlled,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Madan, Ajay, Markison, Stacy, Betz, Stephen F., Krasner, Alan, Luo, Rosa, Jochelson, Theresa, Lickliter, Jason, Struthers, R. Scott
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894159/ https://www.ncbi.nlm.nih.gov/pubmed/35000098 http://dx.doi.org/10.1007/s11102-021-01201-z

Ejemplares similares

SAT-429 Final Results from the First in Man Phase 1 Clinical Trial of CRN00808, an Orally Bioavailable sst2-Selective, Nonpeptide Somatostatin Biased Agonist, for the Treatment of Acromegaly: Safety, Pharmacokinetics, Pharmacodynamics, and Midazolam Drug Interaction in Healthy Volunteers
por: Madan, Ajay, et al.
Publicado: (2019)

Discovery of Paltusotine (CRN00808), a Potent, Selective, and Orally Bioavailable Non-peptide SST2 Agonist
por: Zhao, Jian, et al.
Publicado: (2022)

SAT-169 Selective Nonpeptide Somatostatin Subtype 5 (sst5) Agonists Suppress Glucose- and Sulfonylurea-Induced Insulin Secretion in Rats
por: Sturchler, Emmanuel, et al.
Publicado: (2019)

PSUN304 CRN04777 an Oral, Nonpeptide SST5-selective Somatostatin Agonist Dose Dependently Suppresses Basal and Stimulated Insulin Secretion
por: Ferrara-Cook, Christine, et al.
Publicado: (2022)

MON-089 Discovery and Identification of Late Stage Selective Nonpeptide Somatostatin Subtype 5 (sst5) Agonists for the Treatment of Hyperinsulinemic Hypoglycemia
por: Fowler, Melissa A, et al.
Publicado: (2020)

SAT-260 Selective Nonpeptide Somatostatin Subtype 5 (sst5) Agonists Suppress Induced Insulin Secretion in Pancreatic Islets from both Rats and Healthy Human Donors
por: Rico-Bautista, Elizabeth, et al.
Publicado: (2019)

OR23-05 Human Absorption, Metabolism, Excretion, and Absolute Oral Bioavailability of (14)C-CRN00808, an Orally Bioavailable, Nonpeptide, Selective, Somatostatin Receptor 2 (sST2) Biased Agonist for the Treatment of Acromegaly
por: Madan, Ajay, et al.
Publicado: (2020)

ACROBAT Edge: Safety and Efficacy of Switching Injected SRLs to Oral Paltusotine in Patients With Acromegaly
por: Gadelha, Monica R, et al.
Publicado: (2022)

Safety and Efficacy of Switching Injected Peptide Long-Acting Somatostatin Receptor Ligands to Once Daily Oral Paltusotine: ACROBAT Edge Phase 2 Study
por: Gadelha, Monica R, et al.
Publicado: (2021)

OR19-03 Effects of Nonpeptide Orally Bioavailable ACTH Antagonists on Adrenal Gland Size and Function in Rats
por: Markison, Stacy, et al.
Publicado: (2020)

SAT628 Effect Of Hepatic Impairment On The Pharmacokinetics, Safety, And Tolerability Of Oral Paltusotine, A Non-peptide, Selective Somatostatin Receptor Subtype 2 Agonist
por: Luo, Rosa, et al.
Publicado: (2023)

OR12-2 Inhibition of Basal and ACTH-stimulated Cortisol Secretion in Humans Using an Oral Nonpeptide ACTH Antagonist (CRN04894)
por: Betz, Stephen, et al.
Publicado: (2022)

Selective Somatostatin 5 (SST5) and Somatostatin 2 (SST2) Nonpeptide Agonists Potently Suppress Glucose- and Tolbutamide-Stimulated Dynamic Insulin Secretion From Isolated Human Islets
por: Rico, Elizabeth, et al.
Publicado: (2021)

Effects of CRN04894, a Nonpeptide Orally Bioavailable ACTH Antagonist, on Corticosterone in Rodent Models of ACTH Excess
por: Fowler, Melissa A, et al.
Publicado: (2021)

SAT-364 Nonpeptide Orally-Bioavailable ACTH Antagonists: Suppression of ACTH-Induced Corticosterone Secretion and Adrenal Hypertrophy in Rats
por: Kusnetzow, Ana, et al.
Publicado: (2019)

MON-176 Discovery and Identification of Late Stage Selective Nonpeptide ACTH Antagonists for the Treatment of Cushing’s Disease, Ectopic ACTH Secreting Tumors, and Congenital Adrenal Hyperplasia
por: Kusnetzow, Ana Karin, et al.
Publicado: (2020)

The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets
por: Pivonello, Claudia, et al.
Publicado: (2014)

OR01-01 Oral, Once-daily, Paltusotine (Non-peptide Selective Somatostatin Receptor Subtype 2 Agonist) Therapy In Patients With Acromegaly Is Associated With Long-term Biochemical And Symptom Control And Is Preferred Over Injectable Somatostatin-Receptor Ligands
por: Gadelha, Monica R, et al.
Publicado: (2023)

A selective nonpeptide somatostatin receptor 5 agonist effectively decreases insulin secretion in hyperinsulinism
por: Juliana, Christine A., et al.
Publicado: (2023)

Crosstalk between Growth and Osmoregulation of GHRH-SST-GH-IGF Axis in Triploid Rainbow Trout (Oncorhynchus mykiss)
por: Xiang, Kaiwen, et al.
Publicado: (2022)

FRI538 Discovery And Characterization Of Orally Bioavailable Nonpeptide Thyroid Stimulating Hormone Receptor (TSHR) Antagonists For The Treatment Of Graves’ Disease
por: Fowler, Melissa A, et al.
Publicado: (2023)

Dose–exposure–IGF-I response of once-weekly somapacitan in adults with GH deficiency
por: Kildemoes, Rasmus Juul, et al.
Publicado: (2022)

SAT182 Effects Of An Orally Bioavailable Nonpeptide Parathyroid Hormone Receptor Type 1 (PTH1R) Antagonist In Rodent Models Of Primary Hyperparathyroidism (PHPT)
por: Antwan, Agnes S, et al.
Publicado: (2023)

Prospect of acromegaly therapy: molecular mechanism of clinical drugs octreotide and paltusotine
por: Zhao, Jie, et al.
Publicado: (2023)

Preclinical Activity of Eltrombopag (SB-497115), an Oral, Nonpeptide Thrombopoietin Receptor Agonist
por: Erickson-Miller, Connie L, et al.
Publicado: (2009)

A Nonpeptide Oxytocin Receptor Agonist for a Durable Relief of Inflammatory Pain
por: Hilfiger, Louis, et al.
Publicado: (2020)

Model-Based Analysis of IGF-I Response, Dosing, and Monitoring for Once-Weekly Somapacitan in Children With GH Deficiency
por: Kildemoes, Rasmus J, et al.
Publicado: (2023)

In vitro pharmacological characterization of a novel unbiased NOP receptor‐selective nonpeptide agonist AT‐403
por: Ferrari, Federica, et al.
Publicado: (2017)

Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist
por: Kawai, Takahiro, et al.
Publicado: (2020)

Effects of combination therapy: somatostatin analogues and dopamine agonists on GH and IGF1 levels in acromegaly
por: VALEA, ANA, et al.
Publicado: (2015)

Renoprotective Effects of AVE0991, a Nonpeptide Mas Receptor Agonist, in Experimental Acute Renal Injury
por: Barroso, Lívia Corrêa, et al.
Publicado: (2012)

Nonpeptide Small Molecule Agonist and Antagonist Original Leads for Neuropeptide FF1 and FF2 Receptors
por: Journigan, V. Blair, et al.
Publicado: (2014)

MON-459 ONO-5788, a Novel Oral Small Molecule Somatostatin Receptor Type-2 (SST2) Agonist, Attenuates GH Hypersecretion in Human GH-Secreting, Pituitary Adenoma-Derived Cells
por: Zhou, Cuiqi, et al.
Publicado: (2019)

THU174 Model-Based Analysis Of IGF-I Response, Dosing, And Monitoring For Once-Weekly Somapacitan In Children With GH Deficiency
por: Kildemoes, Rasmus Juul, et al.
Publicado: (2023)

MON-477 Octreotide and ONO-ST-468, a Novel and Potent Somatostatin Receptor Type-2 (SST2) Agonist, Suppress GH Hypersecretion in the Monkey
por: Tanaka, Hirotaka, et al.
Publicado: (2019)

Effects of GH/IGF on the Aging Mitochondria
por: Poudel, Sher Bahadur, et al.
Publicado: (2020)

The Multiple Faces of the GH/IGF Axis
por: Chesnokova, Vera
Publicado: (2022)

Intranasal Human Growth Hormone (hGH) Induces IGF-1 Levels Comparable With Subcutaneous Injection With Lower Systemic Exposure to hGH in Healthy Volunteers
por: Lewis, Andrew L., et al.
Publicado: (2015)

The GH/IGF-1 Axis and Heart Failure
por: Castellano, Graziella, et al.
Publicado: (2009)

Neurotrophic and Neuroregenerative Effects of GH/IGF1
por: Bianchi, Vittorio Emanuele, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_gj2otivmgrv13j8cks3rs73bl5